Clinical trials: Anticoagulation
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT).
- Conditions
- Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury
- Trial name
- NCT02860130
- Testing
- Prismocitrate 18, No Anticoagulation
- Where
- 12 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Vantive Health LLC
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Phase I Study of MT1011 Injection in Healthy Subjects
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects.
- Trial name
- NCT07024160
- Testing
- MT1011
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous…
- Conditions
- Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
- Trial name
- NCT06947707
- Where
- China
- Volunteers
- 1,486 people
- Sponsor
- Xuanwu Hospital, Beijing
Ischemic Stroke, Oral Anticoagulation
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or…
- Conditions
- Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment
- Trial name
- ASPERA (NCT06823466)
- Where
- 47 sites in Croatia, Denmark and 13 more
- Volunteers
- 200 people
- Sponsor
- University of L'Aquila
End Stage Renal Disease on Dialysis, Biocompatibility
Efficiency and Biocompatibility in Hemodiafiltration Procedure
Hemodiafiltration is a modern, increasingly used special hemodialysis method. Compared to hemodialysis, it allows greater clearance of medium- and high-molecular-weight molecules.
- Conditions
- End Stage Renal Disease on Dialysis, Biocompatibility, Anticoagulation, Hemodiafiltration
- Trial name
- NCT06807905
- Testing
- Heparin anticoagulation, Citrate anticoagulation
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- University Medical Centre Ljubljana
Anticoagulation, Lung Transplantation
ROTEM-based Optimization of Anticoagulation Regimens in Lung Transplantation
Extracorporeal membrane oxygenation (ECMO) is now a standard component of intraoperative support during lung transplantation, requiring anticoagulation management, typically with unfractionated heparin (UFH).
- Conditions
- Anticoagulation, Lung Transplantation, Viscoelastic Properties, Unfractionated Heparin
- Trial name
- ROAR-LT (NCT06779162)
- Where
- Czechia
- Volunteers
- 65 people
- Sponsor
- University Hospital, Motol
Anticoagulation
Point-of-Care Testing (POCT) for Guided Precision Anticoagulation With Warfarin: A Multicenter, Non-concurrent Controlled Study
This study aims to compare the key clinical indicators such as the time to achieve INR target, frequency of dose adjustment, and the incidence of thrombotic and hemorrhagic events between Point-of-Care Testing (POCT) and…
- Trial name
- NCT06645275
- Testing
- POCT test
- Volunteers
- 416 people
- Sponsor
- RenJi Hospital
Anticoagulation
Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves
this study aims to comprehensively evaluate the efficacy and safety profiles of rivaroxaban and warfarin during the initial postoperative period following surgical bioprosthetic valve in patients.
- Trial name
- NCT06476301
- Testing
- Rivaroxaban
- Volunteers
- 250 people
- Sponsor
- RenJi Hospital
Anticoagulation Associated (VKA & NOAC) Intracerebral Hemorrhage
Multicenter Analysis of Oral Anticoagulant-associated ICH - Part Two
Intracerebral hemorrhage [ICH] is the most feared complication of oral anticoagulation [OAC], yet therapeutic strategies are limited reflected by overall weak guideline recommendations.
- Trial name
- RETRACE-II (NCT03093233)
- Testing
- no intervention
- Volunteers
- 1,369 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Anticoagulation, Venous Thromboembolism
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay.
- Conditions
- Anticoagulation, Venous Thromboembolism, Atrial Fibrillation
- Trial name
- UniXa (NCT04539301)
- Testing
- Estimated anticoagulant level (conversion factor x anti-Xa activity)
- Where
- France
- Volunteers
- 2,100 people
- Sponsor
- Nantes University Hospital
Critically Ill, Acute Kidney Injury
Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation
The primary objectives of the BiPhox-Trial are to demonstrate, that the use of Biphozyl® as a replacement fluid in adult critically ill acute kidney injury (AKI) patients, results in a lower rate of pH excursions and of…
- Conditions
- Critically Ill, Acute Kidney Injury, Renal Replacement Therapy, Continuous Renal Replacement Therapy
- Trial name
- NCT04071171
- Testing
- CVVH with Phoxilium® in the first 48h after randomization, CVVH with Biphozyl® in the first 48h after randomization, CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)
- Where
- Austria
- Volunteers
- 88 people
- Sponsor
- Medical University Innsbruck
Thromboelastography, Hemodialysis
Preliminary Exploration of Thromboelastography in the Monitoring of Anticoagulation in Maintenance Hemodialysis Patients
Objectives: To investigate the role of thromboelastography parameters (R, K, Angle, MA) in monitoring anticoagulation in maintenance hemodialysis (MHD) patients. Subjects: Two hundred stable MHD patients.
- Conditions
- Thromboelastography, Hemodialysis, Anticoagulation
- Trial name
- NCT06272708
- Where
- China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Embolism and Thrombosis, Anticoagulation
Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis
A single-center, open-label, exploratory randomized controlled study is proposed with the following objectives: whether prolonging the duration of anticoagulation to 12 months, compared with 6 months of routine anticoagulation…
- Trial name
- NCT06209892
- Testing
- Extended anticoagulation
- Volunteers
- 220 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Apheresis, Anticoagulation
Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation
Membrane plasmapheresis is one of the methods for treating immune diseases. Plasmapheresis removes autoantibodies and immune complexes, paraproteins, lipoproteins and reduces the concentration of cytokines.
- Trial name
- NCT05191290
- Testing
- unfractionated heparin, Sodium Citrate
- Where
- Slovenia
- Volunteers
- 15 people
- Sponsor
- University Medical Centre Ljubljana
Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage
Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
The goal of this study is to determine if a fixed dose of 4-factor prothrombin complex concentrate (4FPCC) is as effective as the current standard of care.
- Conditions
- Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
- Trial name
- kcentra (NCT03064035)
- Testing
- 4-factor prothrombin complex concentrate (4FPCC)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- HealthPartners Institute
Anticoagulation and Thrombosis Point of Care Test (AT-POCT)
Point of Care Testing to Improve Monitoring of LVAD Patients
The purpose of this study is to develop and validate the accuracy of a low-cost "point-of-care" test (POCT) that allows monitoring of markers for anticoagulation and thrombosis (local coagulation or clotting of the blood), to be…
- Trial name
- NCT03555552
- Testing
- Anticoagulation and Thrombosis Point of Care Test(AT-POCT), Duke Central Automated Laboratory (DCAL)
- Where
- United States
- Sponsor
- Duke University
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended
The investigators' study aims to test the correlation between CoaguChek point-of-care aPTT testing (Roche, Switzerland) and low plasma levels of all four currently EMA approved direct oral anticoagulants (DOAC; apixaban…
- Trial name
- POCT-DOAC ext (NCT04679298)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Tuebingen
Ischemic Stroke, Intracerebral Hemorrhage
Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime
The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an investigator-initiated study, is a German multicenter, prospective, observational registry.
- Conditions
- Ischemic Stroke, Intracerebral Hemorrhage, Oral Anticoagulation, Cardiovascular Diseases
- Trial name
- RASUNOA-Prime (NCT02533960)
- Testing
- not applicable (observational study)
- Where
- Germany
- Volunteers
- 3,832 people
- Sponsor
- University Hospital Heidelberg
Anticoagulation in Dialysis Patients
Comparison of Point of Care to Lab INR in Dialysis Patients on Warfarin
To determine whether point of care (POC) International Normalized Ratio (INR) test results correlate with plasma INR measures in hemodialysis patients.
- Trial name
- NCT00660946
- Volunteers
- 37 people
- Sponsor
- Mayo Clinic
Critical Illness, Anticoagulation
Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation
The purpose of this study was to compare the efficacy and safety of nafamostat mesylate and unfractionated heparin during ECMO anticoagulation in critically ill patients.
- Trial name
- NCT05555641
- Testing
- Nafamostat Mesylate, Unfractionated Heparin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiaobo Yang, MD